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Abstract 25 
Context: Evidence-based guidelines for active surveillance (AS), a treatment option for men 26 
with low-risk prostate cancer, recommend regular follow-up at periodic intervals to monitor 27 
disease progression.  However, gaps in monitoring can lead to delayed detection of cancer 28 
progression, leading to missed window of curability.  29 
Objective: We aimed to identify the extent to which real-world observational studies reported 30 
adherence to monitoring protocols among prostate cancer patients on AS. When reported, we 31 
sought to characterize definitions of adherence.  32 
Evidence Acquisition: We systematically reviewed observational studies assessing outcomes of 33 
prostate cancer patients on AS, published before March 22, 2019 in PubMed, Embase, and 34 
CENTRAL. Adherence definitions were considered time-bound if they included a pre-specified 35 
time, and binary if adherence was assessed but did not specify a time interval. We assessed 36 
study quality using the Strengthening the Reporting of Observational Studies in Epidemiology 37 
checklist. 38 
Evidence Synthesis: Forty-five studies met our inclusion criteria. Eleven studies did not report 39 
any data on adherence to AS protocols. Twenty-five studies did not explicitly measure 40 
adherence, but provided relevant data (e.g. number of patients who received a repeat biopsy). 41 
Six studies reported adherence using a time-bound definition, while three studies used a binary 42 
definition. Twenty-three studies provided information on patients lost to follow-up.   43 
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Conclusion: Most studies reporting outcomes of patients on AS did not measure or report 44 
adherence. When reported, adherence was often not time-specific. As some AS patients will 45 
benefit from maintaining a window of curability, clinical practices and future studies should 46 
track and report adherence and associated factors.  47 
Patient Summary:  We reviewed real-world observational studies examining outcomes of 48 
prostate cancer patients on AS. Most studies did not clearly define or report adherence to 49 
monitoring protocols, which is important to consider for appropriate disease management.  50 
51 
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Introduction 52 
Prostate cancer is the most common cancer in men in the United States, and second 53 
most common internationally.1,2 Most prostate cancers are low-risk and slow growing; 54 
however, a subset can progress to more lethal disease.3  Active surveillance (AS) is the 55 
recommended standard of care for low- and some intermediate-risk prostate cancers that have 56 
little risk of progression.4 AS defers active treatment (e.g., surgery or radiation) with close 57 
monitoring and leads to active treatment if the cancer progresses (e.g., low grade disease 58 
becomes higher grade disease), the cancer is reclassified (e.g., detected a previously 59 
undetected cancer of higher grade on confirmatory or surveillance biopsy), or the patient 60 
decides to pursue active treatment. AS also provides the opportunity to maintain men’s quality 61 
of life without the potential adverse effects of treatment.5  62 
AS eligibility criteria and monitoring guidelines vary widely by institution, but generally 63 
recommend regular monitoring for disease progression that includes prostate-specific antigen 64 
(PSA) tests, digital rectal exams (DRE), and repeat prostate biopsies at periodic intervals.6  65 
However, the extent of patient adherence to AS protocols is unclear. Little is known about 66 
which populations or settings are more vulnerable to monitoring gaps, or multi-level factors 67 
associated with non-adherence or loss to follow-up (LTFU).  68 
In this systematic review, we sought to identify if and how real-world observational 69 
studies tracked and reported adherence to AS protocols when evaluating outcomes of prostate 70 
cancer patients on AS. Specifically, we aimed to assess whether or not such studies reported 71 
patient adherence to AS protocols (e.g., PSA tests, DREs, repeat biopsies, and duration and 72 
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frequency of monitoring received). When studies reported adherence, we sought to understand 73 
how investigators define and measure adherence, as well as the range of adherence rates.  74 
 75 
Evidence Acquisition 76 
Our review was guided by the PRISMA statement.7 We conducted a systematic literature 77 
search (PROSPERO #CRD42016051128) on March 8, 2018 and updated on March 22, 2019 in 78 
PubMed, Embase, and CENTRAL. We created our search strategy in collaboration with a clinical 79 
librarian (JBW) using text words and controlled vocabulary, including MeSH and Emtree terms 80 
(e.g., “active surveillance” and “Prostatic Neoplasms”[Mesh]). Appendix A details the complete 81 
search strategy.  82 
Study eligibility criteria included: 1) focus on AS for prostate cancer; 2) real-world 83 
observational study reporting actual patient care (e.g., a retrospective medical chart review); 3) 84 
followed a predetermined evidence-based AS clinical eligibility criteria (e.g., PSA level, Gleason 85 
score, stage, number of positive cores, etc.) and an AS monitoring protocol (e.g., National 86 
Comprehensive Cancer Network [NCCN] guidelines – PSA every 6 months, annual DRE and 87 
biopsy);4 and 4) reported outcome data (e.g., survival rates, movement to active treatment, or 88 
LTFU). We excluded non-English studies, studies that evaluated outdated AS protocols, as well 89 
as studies that solely reported on active treatment patients. Clinical trials, interventional 90 
studies, efficacy trials (e.g., study cohorts with a study protocol), or studies comparing different 91 
treatment modalities to test protocols or treatment effectiveness were also excluded.  92 
  Two reviewers (GK, SL) independently screened titles and abstracts to determine 93 
relevancy and eligibility, and completed full text reviews.  A third reviewer (US, BB, or NP) 94 
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reconciled discrepancies.  We collected several data elements on adherence and outcomes 95 
(Table 1).  We categorized studies as reporting adherence if they explicitly included a measure 96 
with the term “adherence” or “compliance”.  We considered the adherence/compliance 97 
definition time-bound if it included the timeliness of monitoring (e.g. patient adherent if repeat 98 
biopsy completed within six months of a designated date). We considered the definition binary 99 
if it assessed adherence, but was not time-bound (e.g. testing received versus not).  We 100 
tabulated adherence definitions and results, when provided. We used the Strengthening the 101 
Reporting of Observational Studies in Epidemiology (STROBE) checklist to assess study quality.8 102 
 103 
Evidence Synthesis 104 
We screened 6,118 articles’ titles and abstracts and reviewed the full text of 267 105 
articles. After applying our inclusion and exclusion criteria, we included 45 studies (Figure 1), 106 
and classified them into four mutually exclusive groups (Figure 2). 107 
Study characteristics 108 
After removing participant sub-groups who did not meet our eligibility criteria (e.g., 109 
enrolled in a randomized controlled trial or who did not undergo AS), we ultimately included a 110 
total of 29,143 participants (range: 34 – 5,302) from 45 studies. The earliest enrollment in an AS 111 
program began in 1990,9,10 culminating as late as 2017.11 112 
 Eligibility criteria into AS programs varied across studies; however, most studies 113 
restricted inclusion by diagnostic criteria – e.g., Gleason score ≤ 6, PSA ≤ 10 ng/ml, ≤ 33% 114 
positive biopsy cores, and ≤ 50% involvement in a single core. Some studies stated they 115 
included select men with higher risk features, such as those with a strong preference for AS.9,12–116 
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19 A few studies considered patients’ cognitive capacity to understand AS programs as well as 117 
their ability to attend follow-up visits.20,21 Eligibility criteria also changed over time in certain 118 
long-term studies, reflecting a general trend in the evolution of AS protocols.9,22–26 119 
 Most studies reported follow-up time on AS, however the measure varied based on 120 
when investigators determined follow-up began (e.g. upon diagnosis or agreement to enroll 121 
into an AS program) and ended (e.g. upon study completion, movement to active treatment, or 122 
other censorship).9,10,12–19,21–24,27–44 Median follow-up time ranged from 16.9 months33 to 6.7 123 
years.31,33 124 
Patient characteristics 125 
All 45 studies reported patient age and clinical characteristics – such as Gleason score, 126 
PSA, number of positive biopsy cores, risk classification, and clinical stage. Fourteen studies 127 
reported patient race/ethnicity.9,11,15,18,19,22,23,35–40,45 Four of these publications specifically 128 
focused on studying racial/ethnic minorities.22,23,35,37 Two studies reported patients’ marital 129 
status.9,19 Two studies also reported tobacco use history;9,23 however, only one also reported 130 
history of substance abuse, mental illness, homelessness, and primary language.23 131 
AS protocols 132 
 Follow-up protocols varied across studies, using strict or modified NCCN,15,18,32,35,36,40,45 133 
Prostate Cancer Research International Active Surveillance (PRIAS),13,25,26,33,43,46,47 Johns 134 
Hopkins,40,42,45 University of California San Francisco,9,11,23,38,48 Epstein,18,20,40–42 and other 135 
institution-specific protocols.49,50 All studies described PSA testing and biopsy schedules. Nine 136 
studies followed a protocol to assess PSA every three months for the first two years on AS, 137 
followed by every six months thereafter.20,24–26,31,33,43,46,47 For all other studies, PSA testing 138 
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intervals ranged from one to 12 months. Repeat biopsy schedules varied widely across studies 139 
as seen in seven publications that biopsied patients annually,17,18,35,40–42,45 and five that biopsied 140 
patients at one, four, seven, and ten years, and every five years thereafter.25,26,43,46,47 Follow-up 141 
protocols also varied by risk level at diagnosis and during follow-up, patient preference, and 142 
patient age.  As with eligibility criteria, protocols changed over time to accommodate evolving 143 
evidence about AS safety and effectiveness.  144 
Reported Adherence  145 
While 11 studies did not report any data on adherence to AS protocols,11–13,18–146 
20,31,32,35,37,45 34 studies reported some form of adherence (e.g. time-bound, binary, or 147 
undefined). 148 
Time-bound Definitions of Adherence 149 
Six studies reported adherence using a time-bound definition.23,25,40,46,47,49 We 150 
considered adherence definitions time-bound if investigators’ definitions included the number 151 
of monitoring events within a specific time interval. Reported adherence rates are included in 152 
Table 2.  153 
No studies had the same adherence definition, although some were similar with varying 154 
degrees of flexibility. For example, Osterberg et al considered patients adherent if they received 155 
a biopsy within 12 months of the scheduled date,23 whereas Tosoian et al, Bul et al, Bokhorst et 156 
al, and Soeterik et al determined patients to be adherent if they received biopsies within six 157 
months of the scheduled date.25,40,46,47 Lee et al did not provide additional time beyond the 158 
recommended interval for a repeat biopsy.49 159 
Binary Definitions of Adherence 160 
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Three studies used binary definitions of adherence that categorized surveillance as 161 
complete or incomplete, but did not include a specific time interval in which monitoring events 162 
needed to take place .30,33,41 For example, Becker et al assessed the proportion of patients that 163 
received four scheduled repeat biopsies.41 Similarly, Sugimoto et al evaluated the proportion of 164 
patients that received their first scheduled repeat biopsy.33 And Hefermehl et al examined the 165 
proportion of PSA tests and biopsies performed compared to the total that should have been 166 
completed.30 We summarize these results in Table 3. 167 
Undefined measures of adherence 168 
 We included 25 studies that did not explicitly define adherence, but either (1) reported 169 
descriptive statistics of follow-up testing rates, including a time frame (such as median time 170 
from diagnosis to first repeat biopsy), or (2) included an incomplete or nonspecific measure of 171 
adherence (such as the absolute number of men who received repeat biopsies, rather than a 172 
proportion).9,10,14–17,21,22,24,26–29,34,36,38,39,42–44,48,50–53  173 
 Twelve studies described the number of follow-up events within a specified time 174 
interval.15,17,21,22,27–29,34,42,44,51,52 Common measures included the time between surveillance 175 
exams and proportion of men who received a follow-up test within a time frame. For example, 176 
Hashine et al reported 55.2% of their cohort received the first repeat biopsy after a median 1.1 177 
years on AS.29 Meunier et al reported a mean of 1.0 ± 0.49 years between repeat biopsies.22  178 
The remaining 13 studies did not define adherence but reported a measure that we 179 
considered representative of adherence.9,10,14,16,24,26,36,38,39,43,48,50,53 For example, some studies 180 
reported the median number of biopsies received10,14,38 and the number of men who received a 181 
follow-up test.9,14,16,24,26,36,38,48,50,53 However, these measures lacked a corresponding time 182 
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frame, such that it is unclear if the tracked biopsies occurred within one year, two, or 183 
throughout the entire study period. Other studies lacked key information, such as the total 184 
number of patients on AS to compare to the number that received follow-up testing.26,50,53  185 
Lost to Follow-Up (LTFU) 186 
 Twenty-three studies provided information on patients LTFU. Rates of LTFU vary from 187 
none52 to 19.5%30, however this measure was not consistently defined across studies making 188 
comparison infeasible. We saw various approaches to defining whether or not a patient was 189 
LTFU. Hefermehl et al considered patients LTFU after no response or information about the 190 
patient more than 12 months after the last scheduled appointment.30 Osterberg et al, 191 
alternatively, considered 31% of patients LTFU after failing to reach them after three attempted 192 
phone calls, until querying a cross-institutional database that indicated only 17.3% of patients 193 
were truly LTFU.23 In addition, some studies excluded patients LTFU.10,39,40,42 194 
Ballas et al examined the association between the chance of being LTFU and 195 
socioeconomic status (SES).35 They found that the cumulative incidence of being LTFU at a 196 
safety-net hospital was significantly higher (57% at 5 years) than at a comprehensive cancer 197 
center (37% at 5 years), and that lower SES was associated with likelihood of being LTFU.  198 
Study Quality and Potential Bias 199 
According to the STROBE checklist,8 the overall quality of studies included was high. 200 
Across most studies, we found limited reporting on confounders related to patient outcomes, 201 
including clearly defined measures of adherence and patient characteristics such as SES, race, 202 
ethnicity, primary language, marital status, and other characteristics shown to influence access 203 
to care. Additionally, not all studies provided details on efforts to address potential sources of 204 
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bias9,12–14,21,24–29,33,34,43,46,48,50,52 or addressed how investigators handled missing 205 
data.9,10,12,14,15,17,18,20–22,24,25,27,28,31,33,34,37,40,43,44,46,47,49–53  206 
 207 
Discussion 208 
The majority of observational studies evaluating clinical outcomes of men on AS do not 209 
measure adherence. When adherence is reported, assessment across studies and settings is 210 
heterogeneous. Not all studies provided a definition of the measure that considers the 211 
timeliness of the routine testing. In addition, a few studies excluded patients LTFU. Since the 212 
premise of AS is routine scheduled monitoring to assess disease progression or reclassification, 213 
timely adherence is essential to retain a window of curability.  Although some studies report no 214 
significant mortality difference between AS and active treatment among men with low-risk 215 
prostate cancer,54,55 adherence to monitoring remains paramount for long-term patient safety, 216 
particularly among a subgroup of patients. Up to 30% of men diagnosed with low- and 217 
intermediate-risk prostate cancer harbor more aggressive disease missed on biopsy,47,56–58 and 218 
some men with higher risk disease may still opt for AS that necessitates regular follow-up.4 219 
African American men may have a higher risk of disease reclassification, as found in a recent 220 
systematic review.59 Additionally, men with intermediate-risk disease who can be safely 221 
monitored on AS have more than a three times higher risk of metastasis at 15-year follow-222 
up.57,60 AS – including the extent to which it is followed - should be reported and studied to 223 
further understand the quality of AS care, resources needed to ensure high-quality monitoring 224 
(e.g., registries), and how protocols can be more widely implemented across diverse settings 225 
and populations safely to prevent overtreatment without compromising quality of life and 226 
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survival. This involves understanding a range of constructs including adherence and various 227 
implementation outcomes, which is critical to understanding the wider implementation and 228 
dissemination of AS in clinical practice.  229 
Most studies did not evaluate the potential impact of multi-level factors on adherence. 230 
For example, only one study examined whether or not patients on AS experienced 231 
homelessness or had a history of mental illness,23 and only two studies detailed how clinics 232 
performed monitoring or responded to patients’ concerns surrounding AS (e.g. a dedicated 233 
nurse conducted follow-up activities and supported patients experiencing anxiety).16,21  Prior 234 
research indicates patient-, provider-, and system-level factors such as these may influence 235 
adherence.61–66 For example, Kinsella et al identified multi-level barriers and facilitators to AS 236 
adherence including cancer characteristics (e.g., lower PSA), patients’ perceived benefits and 237 
harms, social support (e.g., peer support, partner anxiety), receipt of useful information 238 
communicated by providers, healthcare organization and practice (e.g., educational classes on 239 
AS), and health policy factors (e.g., national guidelines).64  We also recognize that adherence to 240 
AS protocols may vary by patient preference (e.g., refuses repeat biopsy), physician practice 241 
(e.g., tailors based on clinical and follow-up characteristics), health care system and country 242 
(e.g., follow NCCN versus the American Urological Association [AUA] guidelines or others),67 243 
and the availability of multi-parametric magnetic resonance imaging.68 Identifying barriers and 244 
facilitators to AS adherence is crucial for successful long-term disease management that delays 245 
or avoids unnecessary treatment until it is warranted, and can inform intervention 246 
development.   247 
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As a framework to examine the interrelated components affecting high quality care, 248 
including adherence, the Chronic Care Model is a promising model for improving management 249 
of chronic conditions.69 AS constitutes ongoing care for a chronic condition; as such, this 250 
framework suggests looking to a health system situated within a community, in which 251 
productive interactions between a prepared, proactive practice team and engaged and active 252 
patients drive positive health outcomes. Patient-centered strategies such as primary care 253 
provider (PCP) and specialty provider coordination, between-visit self-management support, 254 
technology-enabled workflows, as well as organizational support of providers monitoring high-255 
risk populations are promising avenues for safe and effective long-term care.70 Such team-256 
based care and technology interventions present specific opportunities to improve the safety of 257 
outpatient monitoring. For example, PCPs can help ensure appropriate monitoring for their 258 
patients by ordering follow-up tests in collaboration with urology, and electronic medical 259 
record-based alerts and registries can prompt monitoring activities when well-integrated into 260 
care team workflows.70,71 If AS protocols are meant to be effective for detecting prostate cancer 261 
progression, guidelines must incorporate clear and defined adherence measures while offering 262 
care providers and patients guidance on tracking and following monitoring schedules. As 263 
experts call for consensus on AS eligibility criteria, monitoring guidelines, and thresholds for 264 
intervention,6,72 adherence must be measured and considered in the evaluation and selection 265 
of an optimal AS protocol.  266 
Future studies should track and report variables relevant to follow-up care for and 267 
adherence to AS protocols. First, studies should determine a definition of adherence to AS 268 
protocols based on guideline-recommended time (e.g., every 6 months) or a pre-defined grace 269 
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period (e.g. within three months of recommended testing). Second, an adherence rate to 270 
monitoring (e.g., completed PSA testing, annual biopsy and DRE, etc.) should be calculated, 271 
along with the average time between monitoring. Third, studies should also report AS 272 
outcomes, including number and rate patients moved to active treatment, whether due to 273 
disease progression, reclassification, or patient preference.  Lastly, studies should define and 274 
assess LTFU, including associated factors (e.g., race, comorbidities),73 to identify patients at 275 
increased risk.  276 
Even with clear recommendations for monitoring, improving adherence in real-world 277 
clinical settings can be challenging. Fragmented health records and limited resources in safety-278 
net settings can introduce unique barriers to implementing evidence-based recommendations 279 
in prostate cancer care, particularly for AS.74–76 Patient-centered and technology-enabled 280 
solutions to measure and improve adherence must also be designed for and tested in settings 281 
that disproportionately care for low-income and vulnerable populations, many of whom 282 
already face barriers to accessing care.  283 
While we report on studies that include both measures of adherence and compliance, it 284 
is important to differentiate between the two terms, as recommended by the World Health 285 
Organization.77 The former connotes an active agreement between patient and provider: does 286 
the patient adhere to an agreed-upon recommendation? The latter suggests a more passive 287 
role of the patient: does the patient comply with a physician’s orders? When discussing AS, the 288 
success of which is dependent on the patient’s agreement and understanding of follow-up care, 289 
we believe that “adherence” better reflects the inherent shared decision-making paradigm.  290 
 There are limitations to this systematic review. First, since AS protocols differ across 291 
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settings, we could not compare adherence across studies. As a result, we decided to focus on 292 
primary data analysis of real-world observational studies within single or multiple settings using 293 
the same follow-up protocol, rather than secondary data analysis of cancer registries or 294 
consortiums employing various protocols. We also limited our review to studies that had 295 
predetermined evidence-based AS clinical eligibility criteria and monitoring protocols, which 296 
excluded a few studies (e.g., those reporting on the MUSIC consortium).73,78 This was done to 297 
capture studies that intended to follow patients who were clinically appropriate and monitored 298 
based on a predetermined protocol (e.g., NCCN). We also included non-US studies and 299 
recognize that differences in health care systems across countries have implications for 300 
variations in access to and quality of care. However, we hope our review illustrates the need for 301 
consistent definitions and reporting of adherence in order to move towards a standardized AS 302 
protocol. Also, the causality between adherence to AS and patient outcomes is not well 303 
understood due to the focus on short-term outcomes in the literature; however, successful 304 
receipt of timely follow-up visits and testing should be treated as a necessary metric when 305 
reporting AS outcomes.61  306 
To our knowledge, this is the first systematic review that assesses the extent adherence 307 
to follow-up protocols is measured in real-world observational studies reporting outcomes of 308 
men on AS. Due to the large number of men managed by AS, this work offers valuable 309 
implications that may improve the delivery of care for prostate cancer patients on AS. In 310 
addition, previous studies demonstrating differences in prognostic value and prostate cancer 311 
specific mortality for men on AS by race and ethnicity indicate that it is imperative to 312 
thoroughly understand factors associated with successful disease management, including 313 
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adherence, in order to move the needle towards recognizing and reducing disparities.79,80 314 
 315 
Conclusions 316 
Adherence to evidence-based AS protocols is not uniformly reported or defined in the 317 
scientific literature. As AS becomes a more common management strategy among men with 318 
low-risk prostate cancer, our findings highlight the need for more research to: (1) establish 319 
adherence definitions and measures relevant to AS; (2) include adherence as a quality 320 
improvement measure for AS outcomes; and (3) track and identify multilevel factors associated 321 
with adherence and LTFU.  322 
323 
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Figure legends: 611 
Figure 1: PRISMA Flow Diagram 612 
Figure 2: Flow diagram categorizing included studies 613 
614 
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Tables: 615 
Table 1: Data Elements 616 
Study Design  Setting (e.g. private hospital, safety-net, population-based) 
Number of participants 
Country 
Active surveillance (AS) eligibility requirements (e.g. age, tumor grade, prostate-
specific antigen [PSA] level) 
AS monitoring protocol (including testing type and frequency of monitoring) 
Study Group 
Demographics 
Age 
Race/Ethnicity 
Comorbidities 
Social demographics (e.g. Social economic status, homelessness, insurance status) 
Adherence  Definition of adherence as defined by the study 
Any measure of patients adhering to PSA testing schedule 
Any measure of patients adhering to biopsy schedule 
Any measure of patients adhering to digital rectal exam schedule 
Outcome  Definition of lost to follow-up (LTFU) as defined by the study 
Any measure of patients LTFU 
Any measure of patients moved to watchful waiting 
Any measure of patients moved to active treatment 
Any measure of prostate cancer-specific death 
AS = active surveillance; PSA = prostate-specific antigen; LTFU = lost to follow-up 617 
618 
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Table 2: Characteristics of studies measuring adherence using a time-bound definition (n=6)  619 
Study info Cohort 
name 
Study 
period 
Number of 
patients who 
elected Active 
Surveillance 
(AS) 
Adherence 
measure  
Adherence definition Adherence results 
Tosoian et 
al. 201140 
Johns 
Hopkins 
1995-
2010 
796 Adherence to 
repeat 
biopsies 
Patient undergoes 
biopsy within 0.5 
years of designated 
date 
 
Year 1: 92% adherent 
Year 2: 91% adherent 
Total (12 years): 89% (79-
100%) 
Bul et al. 
201346 
 
PRIAS 2006-
2012 
2494 Adherence to 
first repeat 
biopsy 
Patient undergoes 
biopsy within 1.5 
years of initial 
diagnosis 
81% adherent 
Bokhorst et 
al. 201525 
 
PRIAS 2006-
2014 
4547 Adherence to 
scheduled 
prostate-
specific 
antigen (PSA) 
tests  
 
 
At least 3 PSA 
tests/year in first 2 
years, at least 1 PSA 
test/year in following 
years. 
Total: 91% adherent 
 
 Adherence to 
repeat 
biopsies 
 
Biopsy within 6 
months of 
designated date, or 
within 12 months for 
patients with 
prostate-specific 
antigen doubling 
time (PSA-DT) (3-10 
years)  
Year 1: 81% 
Year 4: 60% 
Year 7: 53% 
Year 10: 33% 
Total: 70% 
 
For men with PSA-DT(3-
10): 
Year 2: 24% 
Year 8: 9% 
 
For men with > 4 years of 
follow-up, compliance is 
30% 
Lee et al. 
201049 
 
Kansas 
City 
Veterans 
Affairs 
2004-
2009 
45 Adherence to 
first PSA  
Patient receives 1 of 
4 recommended PSA 
within first year 
Year 1: 100% 
 Adherence to 
first repeat 
biopsy  
Patient receives 1 
biopsy within 1 year  
Year 1: 53.3% 
Osterberg 
et al. 
201723 
 
UCSF 2004-
2014 
104 Proportion of 
patients that 
received 
follow-up 
PSA  
Patient undergoes 
PSA every 3-6 
months 
≥ 1 follow-up PSA: 92%  
Median number of PSA 
tests: 7 (range 1-21).  
 
Year 10: <10% 
 Proportion of 
men that 
received 
Patient undergoes 
biopsy every 12-24 
months 
Average number of 
biopsies: 2 (range 1-5) 
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biopsy  Year 10: <10% 
Soeterik et 
al. 201947 
PRIAS 2008-
2014 
958 Proportion of 
patients that 
received 
recommende
d PSA tests  
Patient receives  
75% recommended 
PSA tests for their 
follow-up duration 
Total: 74% adherent 
(ranged from 55%-83% by 
hospital) 
Proportion of 
patients that 
underwent 
repeat biopsy 
Patient undergoes 
biopsy within 6 
months 
Year 1: Ranged from 48%-
79% by hospital 
 
 
Proportion of 
patients who 
received all 
scheduled 
biopsies  
Patient who should 
undergo  1 biopsy 
misses none within 
follow-up period 
Total: 52% adherent 
(ranged from 40%-68% by 
hospital) 
Abbreviations: AS = active surveillance; PRIAS = Prostate Cancer Research International: Active Surveillance study; 620 
PSA = prostate-specific antigen; PSA-DT = prostate-specific antigen doubling time 621 
 622 
623 
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Table 3: Characteristics of studies measuring adherence using a binary definition (n=3) 624 
Study info Cohort name Study 
period 
Number of patients 
who elected Active 
Surveillance (AS) 
Adherence measure Adherence results 
Becker et al. 
201441 
HAROW 2008-2012 387/748‡ 
 
Proportion that receive 
repeat biopsies 
Biopsy 1: 73.6%  
Biopsy 2: 45.2%  
Biopsy 3: 23.8%  
Biopsy 4: 11.4%  
 
Sugimoto et al. 
201533 
PRIAS-JAPAN 2010-2013 386 Proportion that receive 
first repeat biopsy 
 
Biopsy 1: 75.8%  
Hefermehl et 
al. 201630 
Kantonsspital 
Baden, 
Switzerland 
1999-2013 157 Proportion of 
performed prostate-
specific antigen (PSA) 
tests to total expected 
39.7% of PSA values 
missing 
 
 
 Proportion of 
performed biopsies to 
total expected  
81% men received 
confirmation biopsy, 
19% did not 
 
36.5% biopsies were 
missing 
Abbreviations: AS = active surveillance; HAROW = Hormonal treatment, Active Surveillance, Radiation therapy, OP, Watchful 
waiting study; PRIAS = Prostate Cancer Research International: Active Surveillance study; PSA = prostate-specific antigen 
‡Subset of AS patients monitored by an AS protocol that met our inclusion criteria 
 625 
626 
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Figure 1: PRISMA Flow diagram 627 
  628 
629 
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Figure 2: Flow diagram categorizing included studies   630 
 631 
632 
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Appendix A 633 
Searches run on November 3, 2016, March 8, 2018, and again on March 22, 2019. 634 
No date limits. No language limits. 635 
 636 
PubMed 637 
 638 
("Prostatic Neoplasms"[Mesh] OR “Prostate Neoplasms” OR “Prostate Neoplasm” OR prostate 639 
neoplasm OR prostate neoplasms OR “Prostatic Neoplasm” OR “Prostate Cancer” OR “Prostate 640 
Cancers” OR “Cancer of the Prostate” OR “Prostatic Cancer” OR “Prostatic Cancers” OR “Cancer 641 
of Prostate” OR pca) 642 
 643 
AND ("Watchful Waiting"[Mesh] OR “watchful waiting” OR “active monitoring” OR “watchful 644 
observation” OR “Active Surveillance” OR “surveillance” OR “Expectant Management” OR 645 
“Conservative Management”) 646 
 647 
AND (“low risk” OR low risk OR “early stage” OR “favorable risk” OR favorable risk OR 648 
favourable risk OR “favourable risk” OR indolent OR “clinically localized” OR localized OR 649 
localised OR “clinically insignificant” OR “low grade” OR “lower grade”) 650 
 651 
Initial search on 11/3/16= 2082 652 
Updated search on 3/8/18= 406 653 
Updated search on 3/22/19 = 275 654 
 655 
Embase 656 
 657 
('prostate cancer'/exp OR 'prostate neoplasms' OR 'prostate neoplasm' OR 'prostatic neoplasm' 658 
OR 'prostate cancer' OR 'prostate cancers' OR 'cancer of the prostate' OR 'prostatic cancer' OR 659 
'prostatic cancers' OR 'cancer of prostate' OR pca OR (prostate AND neoplasm) OR (prostate 660 
AND neoplasms)) AND ('watchful waiting' OR 'active monitoring' OR 'watchful observation' OR 661 
'active surveillance' OR 'surveillance' OR 'expectant management' OR 'conservative 662 
management') AND ('low risk' OR 'early stage' OR 'favorable risk' OR indolent OR 'clinically 663 
localized' OR localized OR localised OR 'clinically insignificant' OR 'low grade' OR 'favourable 664 
risk' OR 'lower grade' OR (favorable AND risk) OR (favourable AND risk) OR (low AND risk)) 665 
 666 
Initial search on 11/3/16= 3550 667 
Updated search on 3/8/18= 739 668 
Updated search on 3/22/19 = 686 669 
 670 
CENTRAL 671 
 672 
("Prostatic Neoplasms" OR “Prostate Neoplasms” OR “Prostate Neoplasm” OR prostate 673 
neoplasm OR prostate neoplasms OR “Prostatic Neoplasm” OR “Prostate Cancer” OR “Prostate 674 
40 
 
 
Cancers” OR “Cancer of the Prostate” OR “Prostatic Cancer” OR “Prostatic Cancers” OR “Cancer 675 
of Prostate” OR pca) 676 
 677 
AND (“watchful waiting” OR “active monitoring” OR “watchful observation” OR “Active 678 
Surveillance” OR “surveillance” OR “Expectant Management” OR “Conservative Management”) 679 
 680 
AND (“low risk” OR low risk OR “early stage” OR “favorable risk” OR favorable risk OR 681 
favourable risk OR “favourable risk” OR indolent OR “clinically localized” OR localized OR 682 
localised OR “clinically insignificant” OR “low grade” OR “lower grade”) 683 
 684 
Initial search on 11/3/16= 134 685 
Updated search on 3/8/18= 94 686 
Updated search on 3/22/19 = 57 687 
 688 
All 689 
 690 
Total = 8023 691 
Duplicates= 1907 692 
Final total = 6116 693 
